Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.
Innovative therapy
Targeted therapy
Journal
Cytokine & growth factor reviews
ISSN: 1879-0305
Titre abrégé: Cytokine Growth Factor Rev
Pays: England
ID NLM: 9612306
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
01
02
2021
accepted:
09
02
2021
pubmed:
22
2
2021
medline:
29
9
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
During the Tenth Edition of the Annual Congress on "Anticancer Innovative Therapy" [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell-based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.
Identifiants
pubmed: 33610464
pii: S1359-6101(21)00017-4
doi: 10.1016/j.cytogfr.2021.02.001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : Cancer Research UK
ID : 23110
Pays : United Kingdom
Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.